UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2026

Ultragenyx Pharmaceutical Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-36276**	**27-2546083**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**
60 Leveroni Court **Novato, California**		**94949**
(Address of Principal Executive Offices)		**(Zip Code)**

Registrant's Telephone Number, Including Area Code: 415 483-8800

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.001 par value	RARE	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.01 Completion of Acquisition or Disposition of Assets.

On November 20, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") completed the previously disclosed sale (the "PRV Sale") of its Rare Pediatric Disease Priority Review Voucher ("PRV") to the buyer. The Company was awarded the PRV by the U.S. Food and Drug Administration on September 17, 2026 upon approval of FAYUVI® (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with Sanfilippo syndrome type A.

The PRV Sale was completed pursuant to the terms of an asset purchase agreement dated October 8, 2026 (the "PRV Asset Purchase Agreement"). Pursuant to the PRV Asset Purchase Agreement, the Company received gross proceeds of $203 million from the buyer upon the closing of the PRV Sale. The Company will pay to a third-party licensor $16 million from the sale of the PRV per the terms of a license agreement entered into on October 26, 2026, pursuant to which the Company obtained an exclusive license, in the field of MPS IIIA, to certain of the licensor's patents and patent applications.

The foregoing description of the PRV Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by the full text of the PRV Asset Purchase Agreement, a copy of which will be filed with the Company's Annual Report on Form 10-K for the year ended December 31, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Ultragenyx Pharmaceutical Inc.

Date: November 23, 2026

By: /s/ Howard Horn
Howard Horn
Executive Vice President, Chief Financial Officer, Corporate Strategy